Tumour Necrosis Factor (TNF)

Overview

Tumour Necrosis Factor (TNF), also known as TNF-α or cachectin, is a multifunctional pro-inflammatory cytokine first described by Lloyd J. Old in 1975. It belongs to the cytokine superfamily and is mainly produced by macrophages and monocytes during acute inflammation. TNF can influence a wide range of cellular activities, including cell survival, proliferation, differentiation, and apoptosis.

Originally identified for its ability to induce necrosis in sarcomas and other tumors, Tumour Necrosis Factor (TNF) is now recognized as a misnomer since it is involved not only in tumor regulation but also in numerous pathological and inflammatory conditions. TNF exists in two forms:

1. Membrane-bound TNF
2. Soluble TNF, released after cleavage by the TACE enzyme

It signals primarily through TNF receptors (TNFR1 and TNFR2). TNFR1 initiates apoptosis and inflammatory pathways via NF-κB and MAPK, while TNFR2 regulates immune responses, proliferation, and repair processes.

Symptoms

Excessive or dysregulated Tumour Necrosis Factor activity is linked to various diseases. While TNF itself is not a symptom, its abnormal levels can manifest through clinical features:

1. In systemic inflammation and sepsis: High fever, hypotension, shock
2. In autoimmune disorders (e.g., rheumatoid arthritis, psoriasis):
   1. Joint pain and stiffness
   2. Skin plaques or rashes
   3. Fatigue and malaise
3. In inflammatory bowel disease (IBD):
   1. Abdominal pain
   2. Chronic diarrhea
   3. Weight loss
4. In ocular conditions (uveitis): Vision problems, eye redness, and pain
5. In cancers: Fatigue, weight loss, and immune-related dysfunctions

Persistent elevated Tumour Necrosis Factor is strongly associated with chronic inflammation, tissue damage, and impaired immune balance.

Causes

Several medical conditions and biological responses can cause increased Tumour Necrosis Factor levels:

1. Autoimmune and Inflammatory Disorders:
   1. Rheumatoid arthritis
   2. Psoriatic arthritis and psoriasis
   3. Inflammatory bowel disease (Crohn’s disease, ulcerative colitis)
   4. Ankylosing spondylitis
2. Systemic and Infectious Conditions:
   1. Sepsis and septicemia
   2. AIDS-related complications
   3. Non-infectious uveitis
3. Oncological and Neoplastic Disorders:
   1. Certain cancers, where Tumour Necrosis Factor may contribute to tumor necrosis or growth regulation
4. Other Causes:
   1. Trauma and burns
   2. Metabolic syndrome, obesity, and diabetes (linked with insulin resistance and altered lipid levels)

Thus, Tumour Necrosis Factor is not confined to cancer-related activity but plays a major role in inflammatory and systemic diseases.

Risk Factors

Certain factors increase the likelihood of elevated TNF activity and related disease states:

1. Genetic Susceptibility: Family history of autoimmune or inflammatory disorders.
2. Chronic Infections: Persistent bacterial or viral infections can trigger prolonged TNF release.
3. Metabolic Conditions: High body mass index (BMI), elevated fasting glucose, and HbA1c are associated with raised TNF levels.
4. Immune Dysregulation: Conditions like lupus or juvenile arthritis predispose individuals to abnormal cytokine activity.
5. Age and Lifestyle: Older adults and individuals with poor diet, obesity, or chronic stress show higher TNF expression.
6. Clinical Treatments: Use of anti-TNF biologics may alter test results, occasionally causing false-negative values in laboratory measurements.

These risk factors highlight populations that require monitoring of TNF levels as part of diagnostic or treatment protocols.

Prevention

While TNF activity is a normal immune response, excessive or chronic elevation can be harmful. Preventive strategies focus on reducing triggers of inflammation and monitoring high-risk patients:

1. Regular Health Screenings: Routine testing for TNF-α in patients with autoimmune or chronic inflammatory conditions ensures early detection of disease activity.
2. Lifestyle Modifications: Maintaining a healthy weight, balanced diet, and regular exercise helps reduce systemic inflammation linked to high Tumour Necrosis Factor.
3. Infection Control: Prompt treatment of bacterial and viral infections lowers the risk of prolonged TNF activation.
4. Monitoring High-Risk Groups: Patients with rheumatoid arthritis, IBD, psoriasis, or metabolic syndrome should undergo regular evaluations.
5. Medical Management: Use of targeted therapies (anti-TNF biologics) can effectively reduce TNF-driven inflammation, though care must be taken to avoid masking laboratory results.
6. Proper Sample Handling: For accurate laboratory testing, blood samples must be collected and stored under appropriate conditions (e.g., serum separated rapidly and stored at -70°C).